Dr. Harold Eunwoo Kim, MD

Dr. Kim practices at Karmanos Cancer Center in Detroit, Michigan, part of McLaren Health Care.

Dr. Kim's NPI, 1639198120, was assigned on July 18, 2006. Dr. Kim holds Michigan license 4301060817.

Dr. Kim's primary practice is Karmanos Cancer Center, at 4100 John R, Detroit, MI 48201 in Wayne County. The practice phone is (800) 576-6266.

Dr. Kim's primary practice is Karmanos Cancer Center in Detroit, Michigan, part of McLaren Health Care. Dr. Kim is also affiliated with DMC Harper University Hospital. The medical group on file is Wayne Health. Dmand AI also links Dr. Kim to 1 more hospital and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Kim practices, 3 sites in all. Vendor and product names are available with a free account.

Radiation oncology is Dr. Kim's primary specialty in the NPI Registry, under taxonomy code 2085R0001X. Dr. Kim is licensed in Michigan.

CMS data shows 1,226 Medicare services from Dr. Kim across 15 procedure codes in 2024, for 105 Medicare patients. Medicare paid $86,227 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 105 Medicare patients who saw Dr. Kim in 2024. The largest group is 65 to 74, with 57 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 34% are also on Medicaid. Their average risk score is 2.76, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Kim's median patient age at 69, with 44% women.

In 2017, Dr. Kim wrote 17 Medicare Part D claims. They cover 1 drug, with $315 in total drug cost. In 2016, CMS named 13 claims across 1 drug.

Dr. Kim accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 12 papers to Dr. Kim, published from 2011 to 2023. 2021 was the busiest year, with 3. The most frequent topics are Apoptosis, Carcinoma, Squamous Cell and Cell Line, Tumor. Dr. Kim has published most often in Photochem Photobiol. Dr. Kim's most frequent co-authors are Christopher J. Schultz, MD, Alan C. Hartford, MD, PhD and Eric Mark Horwitz, MD.

Dmand AI links Dr. Kim to 6 clinical trials, 2 of them phase 1 studies. 2 are still active or recruiting. Conditions studied include Adenocarcinoma, Bronchiolo-Alveolar, Hematologic Neoplasms and Mucositis. Barbara Ann Karmanos Cancer Institute sponsors the most, 4.

CMS Open Payments shows 7 general payments to Dr. Kim from 6 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 92% of the total. Medtronic, Inc. paid the most, $55.